6 Feb 2015

VBL Therapeutics Receives European Patent Issuance on Lecinoxoid Platform Technology

Customize font size:

TEL AVIV, Israel, Feb. 6, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases, today announced the issuance by the European Patent Office (EPO) of Patent No. 2348866, entitled "Oxidized Lipid Compounds and Uses Thereof" and covering the compound, pharmaceutical composition, and use of the Company's second generation oral Lecinoxoids. VBL is currently applying its Lecinoxoid technology to anti-inflammatory indications, including psoriasis and ulcerative colitis. This patent provides intellectual property rights in validated European countries through 2029.

"This granted patent is an important addition to VBL's Lecinoxoids intellectual property portfolio, which now includes more than 70 issued patents and pending patent applications worldwide," said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. "VBL is committed to continuing to expand and strengthen our pipeline through multiple layers of intellectual property protection. We look forward to leveraging our second-generation molecules to additional immune-inflammatory indications in broad patient populations."

VBL recently completed two Phase 2 studies evaluating the efficacy of lead Lecinoxoid compound, VB-201, for the treatment of psoriasis and ulcerative colitis. Top line results from both studies are expected in the first quarter of 2015.